Amanda Parkes

University of Wisconsin-Madison
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Purpose: Tarlatamab is a first-in-class, half-life extended bispecific T-cell engager immunotherapy targeting delta-like ligand 3, currently approved for the treatment of adult patients with small cell lung cancer with disease progression on or after platinum-based chemotherapy. In this study, we report tarlatamab exposure–response relationships to inform dose selection in patients with small cell lung cancer. Patients and Methods: Pharmacokinetic data were correlated with therapeutic effect (exposure–response analyses) for efficacy and safety measures using pooled data from the DeLLphi-300 and DeLLphi-301 studies. Efficacy measures included objective response rate, disease control rate, best change from baseline in tumor size, progression-free survival, and overall survival. Safety events included treatment-emergent adverse events (TEAE), treatment-related adverse events, and TEAE of interest, including cytokine release syndrome, neutropenia, and neurologic toxicity such as immune effector cell–associated neurotoxicity syndrome. Effects of patient-specific factors were also assessed. Doses ranging from 0.003 to 100 mg every 2 weeks and 200 mg every 3 weeks were explored. Results: Significant positive exposure–response relationships were established for all evaluated efficacy measures. Near-maximal efficacy was reached at exposures associated with the clinical regimen of 10 mg every 2 weeks. No relationships with exposure were identified for the following grade ≥3 events: TEAE, treatment-related adverse events, cytokine release syndrome, and neurologic toxicity, including immune effector cell–associated neurotoxicity syndrome. A shallow trend was observed for a higher percentage of patients experiencing grade ≥3 neutropenia with higher exposures. Conclusions: This analysis supports a 10-mg every-2-weeks regimen and that no dose adjustment is necessary based on age, race, body weight, immunogenicity, number of prior therapies, or disease burden.

Year:

2025

Purpose: Tarlatamab is a first-in-class, half-life extended bispecific T-cell engager immunotherapy targeting delta-like ligand 3, currently approved for the treatment of adult patients with small cell lung cancer with disease progression on or after platinum-based chemotherapy. In this study, we report tarlatamab exposure–response relationships to inform dose selection in patients with small cell lung cancer. Patients and Methods: Pharmacokinetic data were correlated with therapeutic effect (exposure–response analyses) for efficacy and safety measures using pooled data from the DeLLphi-300 and DeLLphi-301 studies. Efficacy measures included objective response rate, disease control rate, best change from baseline in tumor size, progression-free survival, and overall survival. Safety events included treatment-emergent adverse events (TEAE), treatment-related adverse events, and TEAE of interest, including cytokine release syndrome, neutropenia, and neurologic toxicity such as immune effector cell–associated neurotoxicity syndrome. Effects of patient-specific factors were also assessed. Doses ranging from 0.003 to 100 mg every 2 weeks and 200 mg every 3 weeks were explored. Results: Significant positive exposure–response relationships were established for all evaluated efficacy measures. Near-maximal efficacy was reached at exposures associated with the clinical regimen of 10 mg every 2 weeks. No relationships with exposure were identified for the following grade ≥3 events: TEAE, treatment-related adverse events, cytokine release syndrome, and neurologic toxicity, including immune effector cell–associated neurotoxicity syndrome. A shallow trend was observed for a higher percentage of patients experiencing grade ≥3 neutropenia with higher exposures. Conclusions: This analysis supports a 10-mg every-2-weeks regimen and that no dose adjustment is necessary based on age, race, body weight, immunogenicity, number of prior therapies, or disease burden.

Year:

2025

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported . Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3, has shown durable anticancer activity and manageable safety in previously treated small cell lung cancer (SCLC) in DeLLphi-300 phase I and DeLLphi-301 phase II trials. Here, we report extended follow-up of DeLLphi-300 (median follow-up, 12.1 months [range, 0.2-34.3]) in fully enrolled cohorts treated with tarlatamab ≥10 mg dose administered once every two weeks, once every three weeks, or once on day 1 and once on day 8 of a 21-day cycle (N = 152). Overall, the objective response rate (ORR) was 25.0%; the median duration of response (mDOR) was 11.2 months (95% CI, 6.6 to 22.3), and the median overall survival (mOS) was 17.5 months (95% CI, 11.4 to not estimable [NE]). Among 17 patients receiving 10 mg tarlatamab once every two weeks, the ORR was 35.3%, the mDOR was 14.9 months (95% CI, 3.0 to NE), the mOS was 20.3 months (95% CI, 5.1 to NE), and 29.4% had sustained disease control with time on treatment ≥52 weeks. No new safety signals were identified. In modified Response Assessment in Neuro-Oncology Brain Metastases analyses, CNS tumor shrinkage of ≥30% was observed in 62.5% of patients (10 of 16) who had a baseline CNS lesion of ≥10 mm, including in a subset of patients with tumor shrinkage long after previous brain radiotherapy. In DeLLphi-300 extended follow-up, tarlatamab demonstrated unprecedented survival and potential findings of intracranial activity in previously treated SCLC.

Year:

2024

Year:

2023

Collaborators (6)

Luis Paz-Ares

-

SPAIN
View details

Kai He

The Ohio State University Wexner Medical Center

UNITED STATES
View details

Hossein Borghaei

Professor and Chief, Thoracic Oncology

Fox Chase Cancer Center

UNITED STATES
View details

Philipp J Jost

Chairman

Medical University of Graz

AUSTRIA
View details

ENRIQUETA FELIP

Head Thoracic Oncology Unit (After Competitive Exam)

Hospital Universitari Vall d'Hebron

SPAIN
View details

Afshin Dowlati

-

UNITED STATES
View details